Using a well-established HCC syngeneic cell line model, Hepa1-6, which displays partial response to ICB7, we found that anti-PD1 immunotherapy-treated tumors also had increased PRMT3 mRNA and protein expression (Fig. 2C and Supplementary Fig. 4B), which is consistent with the observed effects in human HCC samples. The gene discussed is PRMT3; the disease is hepatocellular carcinoma.